Washington, D.C.— Congressman Tom Marino (R-PA-10) issued the following statement after requesting that President Donald Trump withdraw his name from consideration to lead the Office of National Drug Control Policy (ONDCP):
“Today I informed President Donald Trump of my intent to withdraw my name from any further consideration to lead ONDCP.
Washington, D.C.—Tomorrow at 1:00 p.m. Congressman Tom Marino (PA-10) will hold a hearing on anticompetitive behavior and the health care marketplace.
Washington, D.C.--Today, the U.S. Food and Drug Administration (FDA) held a public meeting to solicit input in areas where the FDA’s rules are being used in ways that create obstacles and delays. FDA Commissioner Scott Gottlieb, M.D., has shown a commitment to ensuring that generic manufacturers have access to promote competition.
Washington, D.C. — Today, the House passed H.R. 2810, the National Defense Authorization Act (NDAA) for Fiscal Year 2018 by a bipartisan vote of 344-81. Rep. Tom Marino (PA-10) voted in favor of the legislation and released the following statement:
Washington D.C.—Congressman Tom Marino (PA-10) issued the following statement following the Trump administration’s withdrawal of the Waters of the United States rule, commonly referred to as WOTUS.
Washington, D.C. -- Congressman Tom Marino (PA-10) and Congressman John Lewis (GA-05) reintroduced H.R. 2644, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2017.
Washington D.C. – Today, Congressman Tom Marino (PA-10) and Congressman James P. McGovern (MA-02), co-chairs of the Congressional Cystic Fibrosis Caucus, introduced H.Con.Res. 58, a bipartisan resolution to recognize May as Cystic Fibrosis Awareness Month.
Washington D.C. – Today the U.S. House of Representatives passed H.R.1628, the American Health Care Act (AHCA) by a vote of 217-213. Congressman Tom Marino (PA-10) issued the following statement in support of the bill:
Washington D.C. – Rep. Tom Marino (PA-10) released the following statement on possible appointment as Director of the Office of National Drug Control Policy (ONDCP), commonly known as the Drug Czar:
Washington, D.C. – Today, top leaders on the Senate and House Judiciary Committees led by Senator Patrick Leahy (D-VT) introduced legislation to combat anticompetitive practices used by some brand-name pharmaceutical and biologic companies to block entry of lower-cost generic drugs.